
US Patent No: 5,620,687
Number of patents in Portfolio can not be more than 2000
Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
Stats
-
Apr 15, 1997
Issued date -
Dec 30, 1994
filing date -
08/366,860
serial no -
Expired
status
Importance
Loading Importance Indicators...
Abstract
Methods for inhibiting intimal hyperplasia in the vasculature of mammals, including primates, are disclosed. The methods comprise administering to the mammal an anti-PDGF receptor antibody, such as an anti-PDGF-alpha receptor antibody or an anti-PDGF-beta receptor antibody. The methods are useful in reducing intimal hyperplasia due to, for example, vascular injuries resulting from angioplasty, endarterectomy, reduction atherectomy or anastomosis of a vascular graft. The anti-PDGF receptor antibodies may optionally be administered coordinately with heparin, whereby the coordinately administered antibody and heparin are combinatorially effective in inhibiting intimal hyperplasia.
Loading the Abstract Image...
First Claim
Related Publications
Loading Related Publications...
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art
| Patent Info | (Count) | # Cites | Year |
|---|---|---|---|
|
|
|||
| 5,171,217 Method for delivery of smooth muscle cell inhibitors | 269 | 1991 | |
|
|
|||
| 5,268,358 PDGF receptor blocking peptides | 56 | 1991 | |
|
|
|||
| 5,250,519 Non-anticoagulant heparin derivatives | 11 | 1991 | |
|
|
|||
| 5,155,027 Method of producing secreted receptor analogs and biologically active peptide dimers | 71 | 1989 | |